In Reply to "Selpercatinib Controls Central Nervous System Disease in Patients With RET Fusion-Positive NSCLC"

J Thorac Oncol. 2023 May;18(5):e52-e53. doi: 10.1016/j.jtho.2023.02.011.

Authors

Yonina R Murciano-Goroff¹, Sabrina T Lin², Clare Wilhelm¹, Alexia Iasonos², Alexander Drilon³

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
² Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
³ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York. Electronic address: drilona@mskcc.org.

PMID: 37087124
DOI: 10.1016/j.jtho.2023.02.011

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Comment

MeSH terms

Central Nervous System Diseases*
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Proto-Oncogene Proteins c-ret / genetics
Pyrazoles
Pyridines

Substances

selpercatinib
Pyrazoles
Pyridines
RET protein, human
Proto-Oncogene Proteins c-ret

Grants and funding

P30 CA008748/CA/NCI NIH HHS/United States